An Overview of Adalimumab Therapy for Ankylosing Spondylitis.

ABSTRACT:

Background

Ankylosing spondylitis (AS) is a chronic inflammatory disease known for causing pain, stiffness, and reduced mobility in the axial skeleton. Adalimumab, a tumor necrosis factor (TNF) inhibitor, has emerged as a promising therapeutic option for AS.

Methods

This systematic review involved a comprehensive search of randomized controlled trials related to AS treatment, conducted in major databases such as MEDLINE, Google Scholar, and PubMed. The search terms encompassed ankylosing spondylitis, adalimumab, methotrexate, other non-biologic DMARDs, glucocorticoids, NSAIDs, and analgesics. A total of 14 randomized controlled trials with 4,500 participants were included in the review.

Results

The review's results revealed that adalimumab demonstrated notable superio

SUBMITTER: Sukhanova AM 

PROVIDER: S-EPMC11340288 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature